ZYMERON CORPORATION — Department of Defense SBIR Phase II: DHA SBIR DIRECT PHASE II H2D-0243 RAPID SAMPLE PROCESSING DEVICE TO SUPPORT BATTLEFIELD WO
ZYMERON CORPORATION — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,999,983, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Zymeron Corporation won a nearly $3 million Phase II SBIR award from the Defense Health Agency to build a rapid sample processing device. The device will help diagnose wound infections faster in battlefield conditions.
- Amount
- $2,999,983
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- NC
- Period
- 2024-09-20 → 2027-07-19
Technology domains
Description
DHA SBIR DIRECT PHASE II H2D-0243 RAPID SAMPLE PROCESSING DEVICE TO SUPPORT BATTLEFIELD WOUND INFECTION DIAGNOSTICS